Impact of Orlistat-Induced Weight Loss on Diastolic Function and Heart Rate Variability in Severely Obese Subjects with Diabetes
Table 2
Heart rate variability indices in severely obese subjects with type 2 diabetes before and after treatment.
(a) 24 hour
Control group
Treatment group
Pre
Post
Pre
Post
N
13
12
16
16
Mean NN (ms)
768 ± 86
786 ± 111
775 ± 102
796 ± 101
SDNN (ms)
106 ± 34
106 ± 30
102 ± 25
112 ± 23
SDANN (ms)
93 ± 38
91 ± 35
88 ± 22
97 ± 22
rMSSD (ms)
26 ± 15
28 ± 16
24 ± 10
30 ± 10*
pNN50 (%)
7 ± 10
8 ± 10
6 ± 7
9 ± 8*
HF (ln)
4.4 ± 1.0
4.6 ± 0.9
4.5 ± 0.9
4.9 ± 0.7*
LF (ln)
5.6 ± 0.9
5.7 ± 0.7
5.7 ± 1.0
5.9 ± 0.7
LF/HF ratio
3.7 ± 1.9
3.4 ± 1.7
3.3 ± 1.1
2.8 ± 1.3*
(b) Daytime
Control group
Treatment group
Pre
Post
Pre
Post
N
13
12
16
16
Mean NN (ms)
733 ± 100
762 ± 133
734 ± 104
742 ± 105
SDNN (ms)
80 ± 29
85 ± 30
80 ± 22
84 ± 22
SDANN (ms)
68 ± 23
69 ± 26
63 ± 18
66 ± 21
rMSSD (ms)
21 ± 18
26 ± 20
21 ± 8
25 ± 9
pNN50 (%)
5 ± 13
7 ± 13
4 ± 5
6 ± 7
HF (ln)
3.8 ± 1.2
4.3 ± 1.2
4.1 ± 1.0
4.6 ± 0.8
LF (ln)
4.9 ± 0.9
5.4 ± 0.8
5.5 ± 1.0
5.7 ± 0.7
LF/HF ratio
3.8 ± 2.4
3.7 ± 2.5
4.0 ± 1.8
3.2 ± 1.2*
(c) Night time
Control group
Treatment group
Pre
Post
Pre
Post
N
13
12
16
16
Mean NN (ms)
840 ± 86
827 ± 96
851 ± 112
890 ± 105
SDNN (ms)
88 ± 45
86 ± 30
83 ± 25
85 ± 23
SDANN (ms)
57 ± 39
60 ± 31
57 ± 18
53 ± 16
rMSSD (ms)
32 ± 17
30 ± 11
31 ± 15
36 ± 16*
pNN50 (%)
10 ± 12
10 ± 10
11 ± 12
15 ± 14
HF (ln)
5.1 ± 1.1
4.9 ± 0.9
5.0 ± 1.0
5.4 ± 1.0
LF (ln)
6.2 ± 1.1
5.9 ± 0.9
6.0 ± 1.0
6.2 ± 0.9‡
LF/HF ratio
3.7 ± 2.6
3.2 ± 2.0
2.9 ± 1.4
2.6 ± 1.7
Mean ± standard deviation; *: pre versus post; ‡: control versus treatment; ln: logarithmic transformation; HF: High frequency; LF: Low frequency; Mean NN: Mean value of all RR intervals; pNN50: Percentage of intervals differing of ≥50 ms than the preceding interval; rMSSD: square root of the mean squared difference of successive RR intervals; SDANN: Standard deviation of the mean NN intervals for each 5 minutes period; SDNN: Standard deviation of the RR intervals.
